Im­mu­ni­ty­Bio, Coda­genix and Eu­Men­tis raise funds, while a biotech SPAC dis­solves

While Im­mu­ni­ty­Bio is in­volved in ar­bi­tra­tion with Sor­ren­to Ther­a­peu­tics, which filed for bank­rupt­cy this week to pro­tect from the po­ten­tial cap­i­tal bur­den, the Cal­i­for­nia biotech is pulling to­geth­er $50 mil­lion.

The di­rect of­fer­ing could ex­pand up to an­oth­er $60 mil­lion if the undis­closed “mul­ti­ple in­sti­tu­tion­al in­vestors” ex­er­cise the full op­tions on war­rants, Im­mu­ni­ty­Bio said Wednes­day morn­ing. The stock $IBRX slipped about 6% af­ter the open­ing bell.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER